(Q37103927)

18 August 2017

1 reference

title

Plasmodium falciparum malaria vaccines in development (English)

1 reference

Plasmodium falciparum malaria

18 August 2017

0 references

Plasmodium falciparum

0 references

1 reference

1 reference

2

W Ripley Ballou

1 reference

18 August 2017

1

Johan Vekemans

1 reference

18 August 2017

publication date

1 March 2008

1 reference

Expert Review of Vaccines

18 August 2017

published in

1 reference

18 August 2017

volume

7

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

223-240

1 reference

Risk factors for persisting neurological and cognitive impairments following cerebral malaria.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

The entomological inoculation rate and Plasmodium falciparum infection in African children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Ethical considerations related to the provision of care and treatment in vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Genome sequence of the human malaria parasite Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Vaccine-induced immunity to malaria parasites and the need for novel strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Transmission blocking malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoite of the Human Malaria Parasite Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Immunity to non-cerebral severe malaria is acquired after one or two infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Gamma-globulin and acquired immunity to human malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Improving vaccines by incorporating immunological coadjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Viral vectors for malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.223

A genome-wide map of diversity in Plasmodium falciparum

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1038/NG1930

30 October 2021

Identifiers

DOI

10.1586/14760584.7.2.223

1 reference

18 August 2017

1 reference